

innovations

from the University of Vermont

TITLE: MONOCLONAL ANTIBODIES FOR MCJ DETECTION

INVENTORS: Mercedes Rincon, Ph.D. et al.

DESCRIPTION: Loss of expression of the methylation controlled J (MCJ) protein in ovarian cancer has been found to be an indication of poor drug response in patients, and now has been associated by Dr. Rincon and her group with drug response in breast cancer. The Rincon group has developed three monoclonal antibodies against the N-terminus of human MCJ and is currently using the antibodies to confirm the role of MCJ in the response of breast cancer to specific chemotherapy treatment. The anti-MCJ antibodies are currently available for both research and as a potential diagnostic for ovarian, breast and other cancers.

ADVANTAGES: No monoclonal anti-MCJ antibodies exist in the current market today and current diagnosis of ovarian, breast, and other cancers does not include a test for drug response. Use of such a diagnostic tool will help doctors determine the best specific treatment, providing better response and recovery for their patients.

PATENT STATUS: Patent pending

LICENSING STATUS: Worldwide rights available

CONTACT: The Office of Technology Commercialization

Ph: 802-656-8780, innovate@uvm.edu